TCRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
586.0K
-44.2%
1.1M
+7.0%
982.0K
-61.7%
2.6M
+2.2%
2.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
586.0K
-44.2%
1.1M
+7.0%
982.0K
-61.7%
2.6M
+2.2%
2.5M
Operating Expenses
33.6M
+6.6%
31.5M
+4.7%
30.1M
+14.0%
26.4M
-33.2%
39.6M
R&D
25.3M
+8.1%
23.4M
+6.8%
21.9M
+9.3%
20.0M
-36.8%
31.7M
SG&A
8.3M
+2.3%
8.1M
-0.9%
8.2M
+28.7%
6.4M
-18.9%
7.9M
Operating Income
-33031000
-8.3%
-30493000
-4.6%
-29139000
-22.1%
-23858000
+35.6%
-37052000
EBITDA
-32353000
-8.6%
-29794000
-4.7%
-28446000
-23.0%
-23135000
+36.2%
-36285000
Net Income
-33085000
-9.0%
-30359000
-5.9%
-28666000
-24.8%
-22977000
+35.7%
-35710000
EPS (Basic)
$-0.25
-8.7%
$-0.23
-4.5%
$-0.22
-22.2%
$-0.18
+35.7%
$-0.28
EPS (Diluted)
$-0.25
-8.7%
$-0.23
-4.5%
$-0.22
-22.2%
$-0.18
+35.7%
$-0.28
Shares (Diluted)
130.0M
+0.1%
129.9M
+0.0%
129.9M
+0.0%
129.9M
+0.0%
129.8M
TScan Therapeutics (TCRX) — Financials